77 related articles for article (PubMed ID: 16300395)
1. Molecular mechanism of inhibition of nonclassical FGF-1 export.
Rajalingam D; Kumar TK; Soldi R; Graziani I; Prudovsky I; Yu C
Biochemistry; 2005 Nov; 44(47):15472-9. PubMed ID: 16300395
[TBL] [Abstract][Full Text] [Related]
2. Molecular level interactions of S100A13 with amlexanox: inhibitor for formation of the multiprotein complex in the nonclassical pathway of acidic fibroblast growth factor.
Rani SG; Mohan SK; Yu C
Biochemistry; 2010 Mar; 49(11):2585-92. PubMed ID: 20178375
[TBL] [Abstract][Full Text] [Related]
3. The C2A domain of synaptotagmin exhibits a high binding affinity for copper: implications in the formation of the multiprotein FGF release complex.
Rajalingam D; Kumar TK; Yu C
Biochemistry; 2005 Nov; 44(44):14431-42. PubMed ID: 16262243
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, FGF-1 binding, and molecular modeling studies of conformationally flexible heparin mimetic disaccharides.
Liu L; Bytheway I; Karoli T; Fairweather JK; Cochran S; Li C; Ferro V
Bioorg Med Chem Lett; 2008 Jan; 18(1):344-9. PubMed ID: 17981035
[TBL] [Abstract][Full Text] [Related]
5. Synergistic Ca2+ and Cu2+ requirements of the FGF1-S100A13 interaction measured by quartz crystal microbalance: an initial step in amlexanox-reversible non-classical release of FGF1.
Matsunaga H; Ueda H
Neurochem Int; 2008 May; 52(6):1076-85. PubMed ID: 18164517
[TBL] [Abstract][Full Text] [Related]
6. Evidence for serum-deprivation-induced co-release of FGF-1 and S100A13 from astrocytes.
Matsunaga H; Ueda H
Neurochem Int; 2006 Aug; 49(3):294-303. PubMed ID: 16519964
[TBL] [Abstract][Full Text] [Related]
7. A residue-level investigation of the equilibrium unfolding of the C2A domain of synaptotagmin 1.
Anbazhagan V; Wang HM; Lu CS; Yu C
Arch Biochem Biophys; 2009 Oct; 490(2):158-62. PubMed ID: 19723500
[TBL] [Abstract][Full Text] [Related]
8. Solution NMR structure of a human FGF-1 monomer, activated by a hexasaccharide heparin-analogue.
Canales A; Lozano R; López-Méndez B; Angulo J; Ojeda R; Nieto PM; Martín-Lomas M; Giménez-Gallego G; Jiménez-Barbero J
FEBS J; 2006 Oct; 273(20):4716-27. PubMed ID: 16995857
[TBL] [Abstract][Full Text] [Related]
9. Structure of a highly stable mutant of human fibroblast growth factor 1.
Szlachcic A; Zakrzewska M; Krowarsch D; Os V; Helland R; Smalås AO; Otlewski J
Acta Crystallogr D Biol Crystallogr; 2009 Jan; 65(Pt 1):67-73. PubMed ID: 19153468
[TBL] [Abstract][Full Text] [Related]
10. Conformational flexibility of a synthetic glycosylaminoglycan bound to a fibroblast growth factor. FGF-1 recognizes both the (1)C(4) and (2)S(O) conformations of a bioactive heparin-like hexasaccharide.
Canales A; Angulo J; Ojeda R; Bruix M; Fayos R; Lozano R; Giménez-Gallego G; Martín-Lomas M; Nieto PM; Jiménez-Barbero J
J Am Chem Soc; 2005 Apr; 127(16):5778-9. PubMed ID: 15839662
[TBL] [Abstract][Full Text] [Related]
11. Copper binding affinity of S100A13, a key component of the FGF-1 nonclassical copper-dependent release complex.
Sivaraja V; Kumar TK; Rajalingam D; Graziani I; Prudovsky I; Yu C
Biophys J; 2006 Sep; 91(5):1832-43. PubMed ID: 16766622
[TBL] [Abstract][Full Text] [Related]
12. Structural requirements of FGF-1 for receptor binding and translocation into cells.
Zakrzewska M; Krowarsch D; Wiedlocha A; Olsnes S; Otlewski J
Biochemistry; 2006 Dec; 45(51):15338-48. PubMed ID: 17176056
[TBL] [Abstract][Full Text] [Related]
13. S100A13-C2A binary complex structure-a key component in the acidic fibroblast growth factor for the non-classical pathway.
Mohan SK; Rani SG; Kumar SM; Yu C
Biochem Biophys Res Commun; 2009 Mar; 380(3):514-9. PubMed ID: 19284995
[TBL] [Abstract][Full Text] [Related]
14. An experimental and molecular-modeling study of the binding of linked sulfated tetracyclitols to FGF-1 and FGF-2.
Cochran S; Li CP; Bytheway I
Chembiochem; 2005 Oct; 6(10):1882-90. PubMed ID: 16175541
[TBL] [Abstract][Full Text] [Related]
15. Expression of the SNT-1/FRS2 phosphotyrosine binding domain inhibits activation of MAP kinase and PI3-kinase pathways and antiestrogen resistant growth induced by FGF-1 in human breast carcinoma cells.
Manuvakhova M; Thottassery JV; Hays S; Qu Z; Rentz SS; Westbrook L; Kern FG
Oncogene; 2006 Sep; 25(44):6003-14. PubMed ID: 16682955
[TBL] [Abstract][Full Text] [Related]
16. Cell-surface heparan sulfate proteoglycans are essential components of the unconventional export machinery of FGF-2.
Zehe C; Engling A; Wegehingel S; Schäfer T; Nickel W
Proc Natl Acad Sci U S A; 2006 Oct; 103(42):15479-84. PubMed ID: 17030799
[TBL] [Abstract][Full Text] [Related]
17. Understanding the mechanism of the antimitogenic activity of suramin.
Kathir KM; Kumar TK; Yu C
Biochemistry; 2006 Jan; 45(3):899-906. PubMed ID: 16411766
[TBL] [Abstract][Full Text] [Related]
18. The release of fibroblast growth factor-1 from NIH 3T3 cells in response to temperature involves the function of cysteine residues.
Jackson A; Tarantini F; Gamble S; Friedman S; Maciag T
J Biol Chem; 1995 Jan; 270(1):33-6. PubMed ID: 7529229
[TBL] [Abstract][Full Text] [Related]
19. The release of fibroblast growth factor-1 from melanoma cells requires copper ions and is mediated by phosphatidylinositol 3-kinase/Akt intracellular signaling pathway.
Di Serio C; Doria L; Pellerito S; Prudovsky I; Micucci I; Massi D; Landriscina M; Marchionni N; Masotti G; Tarantini F
Cancer Lett; 2008 Aug; 267(1):67-74. PubMed ID: 18400376
[TBL] [Abstract][Full Text] [Related]
20. Spackling the crack: stabilizing human fibroblast growth factor-1 by targeting the N and C terminus beta-strand interactions.
Dubey VK; Lee J; Somasundaram T; Blaber S; Blaber M
J Mol Biol; 2007 Aug; 371(1):256-68. PubMed ID: 17570396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
